caa a22 4500 39759299X CHVBK 20180308164944.0 cr unu---uuuuu 161202e199603 xx s 000 0 eng 10.1093/jac/37.3.565 doi (NATIONALLICENCE)oxford-10.1093/jac/37.3.565 Cefpodoxime proxetil suspension compared with cefaclor suspension for treatment of acute otitis media in paediatric patients [Elektronische Daten] [G. J. Fernández MacLoughlin, D. Gomez Barreto, C. de la Torre, E. A. Pinetta, F. del Castillo, L. Palma] A multicentre open-label, randomised trial was performed to compare the efficacy and safety of cefpodoxime proxetil bd and cefaclor tds in the treatment of acute otitis media in children. A total of 167 children aged from 1 month to 11 years were enrolled in five centres: 78 treated with cefpodoxime and 83 treated with cefaclor, were evaluated in the ITT analysis. After tympanocentesis and culture of middle ear fluid, a pathogen was isolated from 85 (53%) of the 161 evaluable patients for the ITT analysis. The organisms isolated were as follows: Streptococcus pneumoniae: (n = 33, 37.5%); Haemophilus influenzae: (n = 22, 25%); Staphylococcus aureus: (n = 15, 17.1%); Streptococcus pvogenes: (n = 8, 9.1%); Moraxella catarrhalis: (n = 2, 2.3%); others (n = 6, 6.8%). Success (defined as a satisfactory clinical outcome, either cure or improvement) was achieved at the end of treatment, in 93.6% of the patients in the cefpodoxime group and 91.6% of the patients in the cefaclor group (P > 0.05). Clinical recurrence was identified at the follow-up visit (30 days after inclusion), in 6.4% of the cefpodoxime-treated patients and 7.2% of the cefaclor-treated patients (P > 0.05). The drugs were well tolerated by 78/79 (99%) of patients in the cefpodoxime-treated group and 80/85 (94%) in the cefaclor-treated group. The incidence of adverse effects was higher in the cefaclor group than in the cefpodoxime group, but this was not statistically significant (P > 0.05). In conclusion, cefpodoxime proxetil administered bd is as effective as cefaclor administered tds in the treatment of acute otitis media in children. The less frequent dosing schedule of cefpodoxime (bd) compared with cefaclor (tds) appears to be more convenient for the treatment of the infections in children. © 1996 The British Society for Antimicrobial Chemotherapy Original articles nationallicence MacLoughlin G. J. Fernández PAIDEIA, Centro de Pediatria Cerviño 3900 3° piso, Buenos Aires, Argentina aut Barreto D. Gomez Hospital Infantil de México, "Federico Gomez” Mexico aut Torre C. de la Hospital Infantil de México, "Federico Gomez” Mexico aut Pinetta E. A. Hospital "Nuestra Señora del Pilar” Guatemala aut Castillo F. del Paediatric Department, Hospital La Paz Madrid, Spain aut Palma L. Department of ORL, Hospital Pereyra Rossel Montevideo, Uruguay aut Journal of Antimicrobial Chemotherapy Oxford University Press 37/3(1996-03), 565-573 0305-7453 37:3<565 1996 37 jac https://doi.org/10.1093/jac/37.3.565 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1093/jac/37.3.565 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- MacLoughlin G. J. Fernández PAIDEIA, Centro de Pediatria Cerviño 3900 3° piso, Buenos Aires, Argentina aut NATIONALLICENCE 700 1- Barreto D. Gomez Hospital Infantil de México, "Federico Gomez” Mexico aut NATIONALLICENCE 700 1- Torre C. de la Hospital Infantil de México, "Federico Gomez” Mexico aut NATIONALLICENCE 700 1- Pinetta E. A. Hospital "Nuestra Señora del Pilar” Guatemala aut NATIONALLICENCE 700 1- Castillo F. del Paediatric Department, Hospital La Paz Madrid, Spain aut NATIONALLICENCE 700 1- Palma L. Department of ORL, Hospital Pereyra Rossel Montevideo, Uruguay aut NATIONALLICENCE 773 0- Journal of Antimicrobial Chemotherapy Oxford University Press 37/3(1996-03), 565-573 0305-7453 37:3<565 1996 37 jac Metadata rights reserved CC BY-NC-4.0 http://creativecommons.org/licenses/by-nc/4.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-oxford